The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
The AICVD tool can predict the risk of cardiovascular disease.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
It signals Cordis' renewed investment in innovation
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
Subscribe To Our Newsletter & Stay Updated
